T-cell Therapy Market, By Modality, Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), Indication (Hematologic Malignancies, Solid Tumors), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)
Global T-cell Therapy Market is anticipated to reach USD 4.8 billion in 2021 growing at a CAGR of 22.6% during the forecasting period, 2021-2028.
A T-cell is a type of lymphocyte which is responsible for cell-mediated immunity in humans. T-cell therapy is a procedure where chimeric antigen receptor T cells are used. These type of T-cells are genetically modified T-cell which is used to produce artificial T-cell receptor which is used in immunotherapy. The therapy is of 2 types 1. Tumor-infiltrating lymphocytes (or TIL) therapy 2. CAR T-cell therapy.
With increased investment in the sector along with recently increased manufacturing abilities along with government policies are some of the factors that have supported long-term expansion for the T-cell therapy industry.
Global T-cell Therapy Market is segmented into Modality, Therapy, Indication, and geography.
The therapy segment is segmented into T-cell, Tumor-Infiltrating Lymphocytes
Indication segment is segmented into Hematologic Malignancies, Solid Tumors
Geographically, the global T-cell Therapy Market is sub-segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America and insights are provided for each region and major countries within the regions
Key players in the global T-cell Therapy Market are Novartis AG; Merck KGaA; Gilead Sciences, Inc.; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Fate Therapeutics; Pfizer Inc.; Amgen; Celgene Corporation among others.
Report Feature |
Descriptions |
---|---|
Market Revenue In 2021 |
USD 4.8 billion |
Growth Rate |
CAGR of 22.6% during the forecasting period, 2021-2028 |
Historical Data |
2018-2019 |
Forecast Years |
2021-2028 |
Base Year |
2020 |
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
Report Segmentation |
Modality, Therapy, Indication, and Geography |
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East and Africa |
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
Companies Profiled |
Novartis AG; Merck KGaA; Gilead Sciences, Inc.; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Fate Therapeutics; Pfizer Inc.; Amgen; Celgene Corporation |
Available Customization |
In addition to the market data for Global T-cell Therapy Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement. |